Brain Delivery of Drug and MRI Contrast Agent: Detection and Quantitative Determination of Brain Deposition of CPT-Glu Using LC-MS/MS and Gd-DTPA Using Magnetic Resonance Imaging

Molecular Pharmaceutics

Volumn 13, Issue 2, 2016, Pages 379-390

  Tabanor, Kayann ^a   Lee, Phil ^b,c   Kiptoo, Paul ^a   Choi, In Young ^b,c   Sherry, Erica B ^b   Eagle, Cheyenne Sun ^a   Williams, Todd D ^a   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

blood brain barrier (BBB); brain delivery; camptothecin; Gd DTPA; HAV peptide; LC MS MS; magnetic resonance imaging (MRI)

Indexed keywords

CAMPTOTHECIN; GADOLINIUM PENTETATE; GLUTAMIC ACID; HISTIDYLALANYLVALINE 6; PEPTIDE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN HOMOGENATE; BRAIN PERFUSION; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; ANIMAL; DRUG EFFECTS; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAMPTOTHECIN; CHROMATOGRAPHY, LIQUID; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; GADOLINIUM DTPA; GLUTAMIC ACID; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84957310077     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00607     Document Type: Article

References (41)

1. Laksitorini, M.; Prasasty, V. D.; Kiptoo, P. K.; Siahaan, T. J. Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers Ther. Delivery 2014, 5 (10) 1143-63 10.4155/tde.14.67
2. Abbott, N. J.; Patabendige, A. A.; Dolman, D. E.; Yusof, S. R.; Begley, D. J. Structure and function of the blood-brain barrier Neurobiol. Dis. 2010, 37 (1) 13-25 10.1016/j.nbd.2009.07.030
3. Reichel, A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept Chem. Biodiversity 2009, 6 (11) 2030-49 10.1002/cbdv.200900103
4. Pardridge, W. M. Alzheimer's disease drug development and the problem of the blood-brain barrier Alzheimer's Dementia 2009, 5 (5) 427-32 10.1016/j.jalz.2009.06.003
5. McCaffrey, G.; Davis, T. P. Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery J. Invest. Med. 2012, 60 (8) 1131-40 10.231/JIM.0b013e318276de79
6. Mandery, K.; Glaeser, H.; Fromm, M. F. Interaction of innovative small molecule drugs used for cancer therapy with drug transporters Br. J. Pharmacol. 2012, 165 (2) 345-62 10.1111/j.1476-5381.2011.01618.x
7. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiol. Dis. 2010, 37 (1) 48-57 10.1016/j.nbd.2009.07.028
8. Wolburg, H.; Lippoldt, A. Tight junctions of the blood-brain barrier: development, composition and regulation Vasc. Pharmacol. 2002, 38 (6) 323-37 10.1016/S1537-1891(02)00200-8
9. Wheeler, G. N.; Parker, A. E.; Thomas, P. A.; Ataliotis, P.; Poynter, D.; Arnemann, J.; Rutman, A. J.; Pidsley, S. C.; Watt, F. M.; Rees, D. A.; Buxton, R. S.; Magee, A. I. Desmosomal glycoprotein DGI, a component of intercellular desmosome junctions, is related to cadherin family of cell adhesion molecules Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 4796-800 10.1073/pnas.88.11.4796
10. Kiptoo, P.; Sinaga, E.; Calcagno, A. M.; Zhao, H.; Kobayashi, N.; Tambunan, U. S.; Siahaan, T. J. Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides Mol. Pharmaceutics 2011, 8 (1) 239-49 10.1021/mp100293m
11. Laksitorini, M. D.; Kiptoo, P. K.; On, N. H.; Thliveris, J. A.; Miller, D. W.; Siahaan, T. J. Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability J. Pharm. Sci. 2015, 104 (3) 1065-75 10.1002/jps.24309
12. On, N. H.; Kiptoo, P.; Siahaan, T. J.; Miller, D. W. Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide Mol. Pharmaceutics 2014, 11 (3) 974-81 10.1021/mp400624v
13. Sinaga, E.; Jois, S. D.; Avery, M.; Makagiansar, I. T.; Tambunan, U. S.; Audus, K. L.; Siahaan, T. J. Increasing paracellular porosity by E-cadherin peptides: discovery of bulge and groove regions in the EC1-domain of E-cadherin Pharm. Res. 2002, 19 (8) 1170-9 10.1023/A:1019850226631
14. Makagiansar, I.; Avery, M.; Hu, Y.; Audus, K. L.; Siahaan, T. J. Improving the selectivity of HAV-peptides in modulating E-cadherin-E-cadherin interactions in the intercellular junction of MDCK cell monolayers Pharm. Res. 2001, 18, 446-553 10.1023/A:1011094025008
15. Greenwald, R. B.; Pendri, A.; Zhao, H. Stereoselective acylation of 20-(S)-camptothecin with amino acid derivatives using scandium triflate/DMAP Tetrahedron: Asymmetry 1998, 9 (6) 915-918 10.1016/S0957-4166(98)00056-1
16. Kim, J.; Choi, I. Y.; Michaelis, M. L.; Lee, P. Quantitative in vivo measurement of early axonal transport deficits in a triple transgenic mouse model of Alzheimer's disease using manganese-enhanced MRI NeuroImage 2011, 56 (3) 1286-92 10.1016/j.neuroimage.2011.02.039
17. Khan, S.; Ahmad, A.; Guo, W.; Wang, Y. F.; Abu-Qare, A.; Ahmad, I. A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38) J. Pharm. Biomed. Anal. 2005, 37 (1) 135-42 10.1016/j.jpba.2004.09.053
18. Martins, S. M.; Wendling, T.; Goncalves, V. M.; Sarmento, B.; Ferreira, D. C. Development and validation of a simple reversed-phase HPLC method for the determination of camptothecin in animal organs following administration in solid lipid nanoparticles J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2012, 880 (1) 100-7 10.1016/j.jchromb.2011.11.023
19. Liu, X.; Tu, M.; Kelly, R. S.; Chen, C.; Smith, B. J. Development of a computational approach to predict blood-brain barrier permeability Drug Metab. Dispos. 2004, 32 (1) 132-9 10.1124/dmd.32.1.132
20. Takasato, Y.; Rapoport, S. I.; Smith, Q. R. An in situ brain perfusion technique to study cerebrovascular transport in the rat Am. J. Physiol. 1984, 247 (3 Part 2) H484-93
21. Lee, P.; Kim, J.; Williams, R.; Sandhir, R.; Gregory, E.; Brooks, W. M.; Berman, N. E. Effects of aging on blood brain barrier and matrix metalloproteases following controlled cortical impact in mice Exp. Neurol. 2012, 234 (1) 50-61 10.1016/j.expneurol.2011.12.016
22. Steger-Hartmann, T.; Hofmeister, R.; Ernst, R.; Pietsch, H.; Sieber, M. A.; Walter, J. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis Invest. Radiol. 2010, 45 (9) 520-8 10.1097/RLI.0b013e3181e960c9
23. Kroll, R. A.; Neuwelt, E. A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means Neurosurgery 1998, 42 (5) 1083-99 10.1097/00006123-199805000-00082
24. Kroll, R. A.; Pagel, M. A.; Muldoon, L. L.; Roman-Goldstein, S.; Fiamengo, S. A.; Neuwelt, E. A. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers Neurosurgery 1998, 43 (4) 879-86 10.1097/00006123-199810000-00090
25. Neuwelt, E. A.; Hill, S. A.; Frenkel, E. P. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening Neurosurgery 1984, 15 (3) 362-6 10.1227/00006123-198409000-00011
26. Dean, R. L.; Emerich, D. F.; Hasler, B. P.; Bartus, R. T. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone Neuro-Oncology 1999, 1 (4) 268-74 10.1093/neuonc/1.4.268
27. Tomicic, M. T.; Kaina, B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors Biochim. Biophys. Acta, Rev. Cancer 2013, 1835 (1) 11-27 10.1016/j.bbcan.2012.09.002
28. Tsai, T. H.; Chen, Y. F.; Chou, C. J.; Chen, C. F. Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection J. Chromatogr A 2000, 870 (1-2) 221-6 10.1016/S0021-9673(99)00854-7
29. Fox, M. E.; Guillaudeu, S.; Frechet, J. M.; Jerger, K.; Macaraeg, N.; Szoka, F. C. Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates Mol. Pharmaceutics 2009, 6 (5) 1562-72 10.1021/mp9001206
30. Deshmukh, M.; Chao, P.; Kutscher, H. L.; Gao, D.; Sinko, P. J. A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity J. Med. Chem. 2010, 53 (3) 1038-47 10.1021/jm901029n
31. Smith, D. H.; Christensen, I. J.; Jensen, N. F.; Markussen, B.; Romer, M. U.; Nygard, S. B.; Muller, S.; Nielsen, H. J.; Brunner, N.; Nielsen, K. V. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort PLoS One 2013, 8 (4) e60613 10.1371/journal.pone.0060613
32. Baczek, T.; Konieczna, L.; Belka, M.; Maciejka-Kapuscinska, L.; Wisniewski, J.; Niedzwiecki, M.; Balcerska, A.; Adamkiewicz-Drozynska, E.; Wachowiak, J. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis J. Pharm. Biomed. Anal. 2012, 70, 330-6 10.1016/j.jpba.2012.05.012
33. Zhao, H.; Lee, C.; Sai, P.; Choe, Y. H.; Boro, M.; Pendri, A.; Guan, S.; Greenwald, R. B. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization J. Org. Chem. 2000, 65 (15) 4601-6 10.1021/jo000221n
34. Norbedo, S.; Dinon, F.; Bergamin, M.; Bosi, S.; Aroulmoji, V.; Khan, R.; Murano, E. Synthesis of 6-amino-6-deoxyhyaluronan as an intermediate for conjugation with carboxylate-containing compounds: application to hyaluronan-camptothecin conjugates Carbohydr. Res. 2009, 344 (1) 98-104 10.1016/j.carres.2008.09.027
35. Henne, W. A.; Doorneweerd, D. D.; Hilgenbrink, A. R.; Kularatne, S. A.; Low, P. S. Synthesis and activity of a folate peptide camptothecin prodrug Bioorg. Med. Chem. Lett. 2006, 16 (20) 5350-5 10.1016/j.bmcl.2006.07.076
36. Liehr, J. G.; Harris, N. J.; Mendoza, J.; Ahmed, A. E.; Giovanella, B. C. Pharmacology of camptothecin esters Ann. N. Y. Acad. Sci. 2000, 922, 216-23 10.1111/j.1749-6632.2000.tb07040.x
37. Mi, Z.; Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components Biochemistry 1994, 33 (34) 10325-36 10.1021/bi00200a013
38. Burke, T. G.; Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J. Med. Chem. 1994, 37 (1) 40-6 10.1021/jm00027a005
39. Guidance for Industry-Bioanalytical method validation; U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM). May 2001, pp 1-25.
40. Hardee, M. E.; Zagzag, D. Mechanisms of glioma-associated neovascularization Am. J. Pathol. 2012, 181 (4) 1126-41 10.1016/j.ajpath.2012.06.030
41. Alaofi, A.; On, N.; Kiptoo, P.; Williams, T. D.; Miller, D. W.; Siahaan, T. J. Comparison of linear and cyclic HAV peptides in modulating the blood-brain barrier permeability: Impact on delivery of molecules to the brain. J. Pharm. Sci. 2015, in press